Nevertheless these preliminary data address the possibility of producing variant PTPN22 allele selective inhibition by using short interfering RNA duplexes [70] as a novel immunotherapeutic approach to T1DM. This evidence concerns the gene PTPN22 and type 1 diabetes mellitus.